Market Outlook
By 2032, the U.S. Companion Animal Medical Devices Market is expected to reach approximately USD 7.48 billion, expanding at a CAGR of 9.84% during the forecast period 2027–2032. The market stood at USD 4.26 billion in 2026, following historical values of approximately USD 3.15 billion in 2023, USD 3.48 billion in 2024, and USD 3.85 billion in 2025. Values in this report are expressed in USD billions.
The U.S. companion animal medical devices industry sits at the convergence of advanced human-grade medtech translation, pet humanization, escalating veterinary specialty consolidation, clinical workflow transformation, and surging pet health insurance penetration. Clinical demand is underpinned by an unprecedented volume of companion pets, rising life expectancy among canines and felines, and an escalating prevalence of degenerative, oncologic, cardiovascular, and traumatic conditions requiring sophisticated diagnostic and interventional technology. In 2024, approximately 66% of U.S. households, representing roughly 86.9 million homes, owned at least one pet, with dogs and cats accounting for more than 140 million companion animals nationwide. Osteoarthritis, degenerative joint disease, cranial cruciate ligament ruptures, chronic kidney disease, valvular heart disease, spinal compressive disorders, and soft-tissue neoplasia represent durable drivers of advanced capital equipment and recurring interventional consumable utilization across the country.
Canine cranial cruciate ligament disease and orthopedic disorders represent one of the most commercially durable device ecosystems. Over 1.2 million canine surgical stabilization procedures are performed annually across U.S. veterinary clinics and surgical referral centers, generating immense demand for tibial plateau leveling osteotomy plates, locking screw systems, total hip replacement implants, biomaterials, and specialized orthopedic instrumentation. Simultaneously, feline medical management is transitioning toward advanced clinical intervention, where chronic kidney disease, which affects over 30% of geriatric cats, alongside hypertrophic cardiomyopathy, feline lower urinary tract disease, and dental resorptive lesions, drives specialized infusion therapy, micro-endoscopy, digital dental radiography, and continuous blood pressure monitoring.
Cardiopulmonary, critical care, and minimally invasive surgical modalities create an expanding high-frequency device ecosystem. The diagnostic recognition of canine myxomatous mitral valve disease, affecting approximately 10% of all dogs presenting to primary care and upward of 60% of aged small-to-medium breeds, combined with congestive heart failure and acute respiratory distress, has created a structural runway for advanced multi-parameter monitors, veterinary-specific mechanical ventilators, capnographs, oxygen concentrators, and interventional vascular access devices. Under-instrumentation in veterinary intensive care units has rapidly diminished as specialty hospitals and emergency networks upgrade capital equipment fleets to match the acuity management standards of human tertiary care.
The companion animal medical devices market is experiencing an accelerated transition from basic, analog clinical tools toward digital, connected, human-derived, and veterinary-purpose-engineered medical platforms. Wireless multi-parameter telemetry, point-of-care veterinary ultrasound, high-resolution low-dose digital radiography, mobile veterinary computed tomography, laser surgical systems, smart infusion pumps with dose-error reduction systems, and artificial intelligence-assisted image interpretation algorithms are fundamentally reshaping veterinary clinical practice. Medical device manufacturers that provide comprehensive clinical ecosystems combining diagnostic hardware, surgical precision platforms, procedure-specific consumables, cloud connectivity, integrated practice management software interfaces, and structured technical service contracts are establishing an unassailable strategic advantage over companies offering isolated, commoditized hardware.
The historical market trajectory reflected steady resilience and capital equipment modernization as private equity-backed corporate veterinary consolidators acquired thousands of independent practices, injected substantial capital expenditure budgets, standardized clinical device fleets, and expanded high-margin surgical and emergency service lines. From 2027 through 2032, commercial expansion will become progressively propelled by the clinical mainstreaming of veterinary minimally invasive surgery, expanding pet health insurance reimbursement density, advanced orthopedic and neurological interventions, customized 3D-printed titanium implants, and the proliferation of specialty 24-hour emergency hospitals across rapidly growing metropolitan corridors.
Introduction
According to the U.S. Companion Animal Medical Devices Market Report, veterinary clinical medicine in the United States has evolved from transactional, symptom-reactive primary care into a highly specialized, multi-disciplinary continuum that mirrors modern human healthcare delivery. Companion animals regularly progress through a clinical journey that begins with wellness screening, point-of-care digital imaging, and routine dental radiography in community general practices, escalates to advanced cross-sectional imaging such as computed tomography or magnetic resonance imaging in regional specialty referral centers, and culminates in complex orthopedic reconstruction, laparoscopy, interventional cardiology, or intensive care life support. This continuum fosters an expansive commercial marketplace populated by both multi-year capital hardware assets and high-turnover single-use surgical consumables.
Diagnostic imaging and patient monitoring devices form the foundational pillar of modern veterinary infrastructure, representing approximately 41.2% of total U.S. companion animal medical device revenue in 2025. This comprehensive category encompasses veterinary digital radiography systems, cart-based and handheld point-of-care ultrasound platforms, dedicated veterinary CT scanners, high-field MRI systems, rigid and flexible video endoscopes, multi-parameter vital signs monitors, capnography units, and non-invasive blood pressure monitors. The underlying commercial architecture is particularly robust because capital placement of imaging and monitoring platforms locks practices into proprietary service contracts, software licensing subscriptions, software-as-a-service artificial intelligence diagnostic pipelines, and ongoing consumable supply streams including specialized transducer covers, ultrasound gels, biopsy needles, endoscopic snares, and patient monitoring leads.
Veterinary hospitals, specialty surgical centers, and 24-hour emergency referral networks represent the primary engine of high-tier capital expenditure. These facilities account for roughly 62.4% of total device procurement expenditure across the country. Advanced veterinary referral hospitals routinely operate four to eight dedicated operating suites equipped with veterinary-specific anesthesia delivery systems with integrated active scavenging, multi-frequency electrosurgical generators, advanced vessel sealing devices, rigid laparoscopy towers, surgical operating microscopes, and high-frequency orthopedic surgical power tools. The procurement economics within corporate-owned specialty networks are heavily dictated by clinical throughput, anesthesia safety records, surgical complication minimization, equipment uptime, and seamless integration with veterinary picture archiving and communication systems and electronic medical record platforms.
The clinical workflow and capital procurement dynamics of veterinary medical devices diverge significantly from human healthcare procurement models. Because the U.S. veterinary care sector operates almost entirely as a private-pay ecosystem, capital acquisition decisions are unencumbered by human Centers for Medicare and Medicaid Services reimbursement codes, diagnosis-related group payment caps, or third-party commercial health insurance fee-for-service negotiations. Instead, practice owners, corporate procurement committees, and clinical medical directors make return-on-investment evaluations based on procedural billing revenue, client willingness to pay, procedure execution time, staff operational efficiency, and clinical risk mitigation. When an advanced digital radiography suite, high-resolution ultrasound system, or orthopedic surgical set generates cash-flow positive returns within twelve to twenty-four months through direct client fee billing, capital allocation barriers decrease substantially.
Pet health insurance penetration is simultaneously reconstructing veterinary healthcare economics across the United States. Insured pets in North America exceeded 6.25 million animals by 2024, with the United States representing over 85% of total covered lives, generating more than USD 3.9 billion in gross written premiums. Insured dogs and cats utilize veterinary healthcare services at a rate 2.5 to 3 times greater than uninsured pets, and their owners exhibit minimal resistance toward advanced diagnostics, specialized surgical interventions, and intensive critical care. Pet health insurance functions as a structural catalyst for advanced medical device utilization, shielding veterinary surgeons from financial euthanasia discussions and enabling the routine deployment of advanced fracture fixation plates, minimally invasive laparoscopes, multi-modality diagnostic imaging, and prolonged intensive care life-support platforms.
From 2027 through 2032, market dominance within the U.S. companion animal medical devices space will be captured by medtech manufacturers that master the integration of connected clinical ecosystems. The competitive standard will no longer be defined by standalone technical specifications such as imaging pixel pitch or electrosurgical wattage alone. Success will be determined by a vendor’s ability to unify diagnostic acquisition, artificial intelligence-assisted clinical decision support, cloud-based image storage, surgical workflow streamlining, automated inventory tracking for sterile implants, remote equipment diagnostic monitoring, and robust clinical training academies for veterinary professionals.
Key Market Drivers: What’s Fueling the U.S. Companion Animal Medical Devices Market Boom?
The foremost growth driver is the cultural pet humanization phenomenon and the sociodemographic elevation of companion animals to core family member status. More than 85% of U.S. pet owners regard their dogs and cats as integral family members, a cultural sentiment that has dramatically expanded consumer willingness to authorize advanced, human-grade medical and surgical therapies. Pet owners routinely pursue complex total hip replacements, neurosurgical spinal decompressive laminectomies, oncologic tumor resections with advanced vessel sealers, interventional cardiology procedures for congenital heart defects, and intensive mechanical ventilation for acute pulmonary failure. This emotional attachment translates into sustained demand for high-tier medical equipment capable of delivering clinical outcomes comparable to human medical centers.
A second critical market driver is the rapid consolidation of the U.S. veterinary care delivery ecosystem by corporate veterinary conglomerates and private equity-backed management organizations. Consolidation entities such as Mars Veterinary Health (encompassing VCA Animal Hospitals, Banfield Pet Hospital, and BluePearl Specialty and Emergency Medicine), National Veterinary Associates, Thrive Pet Healthcare, Pathway Vet Alliance, and Amerivet have acquired thousands of previously fragmented, independent general and specialty practices. Corporate consolidators centralize capital procurement, enforce standardized clinical care protocols, and deploy institutional balance sheets to aggressively upgrade diagnostic and surgical device fleets. Corporate-owned specialty hospitals systematically invest in advanced multislice CT scanners, 1.5T MRI systems, laparoscopy towers, advanced monitoring suites, and high-frequency electrosurgical units, dramatically accelerating capital device turnover and fleet standardization across hundreds of clinical sites simultaneously.
A third driver is the exponential expansion of the U.S. pet health insurance sector. With insured companion animals growing at a sustained compound annual rate exceeding 16% over recent years, pet insurance has dismantled historical financial boundaries in veterinary medicine. Traditional out-of-pocket veterinary expenditures often forced pet owners to select conservative medical management or economic euthanasia when faced with catastrophic surgical or critical care estimates exceeding several thousand dollars. Pet insurance policies, which typically reimburse between 70% and 90% of eligible medical costs after deductibles, empower veterinarians to recommend and execute comprehensive diagnostic workups, advanced cross-sectional imaging, orthopedic internal fixation, blood gas monitoring, and continuous mechanical ventilation without economic friction.
A fourth driver is the expanding geriatric pet demographic resulting from advances in companion animal nutrition, preventive veterinary medicine, vaccination coverage, and parasitic control. Approximately 50% of the U.S. pet dog and cat population is classified as senior or geriatric, defined generally as animals aged seven years and older. Advanced age brings a commensurate surge in chronic, degenerative, and multi-systemic morbidities, including canine osteoarthritis, spondylosis, degenerative myelopathy, chronic kidney disease, periodontal disease, diabetes mellitus, cardiovascular degenerations, and diverse soft-tissue and bone neoplasias. Managing this aging patient base requires continuous, longitudinal diagnostic monitoring, specialized dental delivery units with integrated digital sensors, orthopedic implants, fluid therapy management via micro-infusion pumps, and advanced surgical resective equipment.
A fifth driver is the direct translation and adaptation of human medical device innovations into the veterinary clinical sphere. Top-tier veterinary device manufacturers have established specialized veterinary divisions or entered distribution partnerships with human medtech corporations to modify proven human technologies for quadrupeds. High-definition 4K rigid endoscopes, vascular sealing platforms, automated wireless telemetry systems, ultrasonic surgical aspirators, and locking compression plates originally developed for human orthopedic trauma are systematically re-engineered with veterinary-specific geometries, anatomical dimensions, and user interfaces. This technology crossover substantially curtails initial research and development timelines, accelerates clinical adoption, and equips veterinary specialists with instrumentation that meets rigorous human healthcare performance benchmarks.
A sixth driver is the acute, structural labor shortage of veterinary surgeons, general practice veterinarians, and credentialed veterinary technicians across the United States. Veterinary practices are confronted by severe capacity bottlenecks and surging patient caseloads. Consequently, veterinary practice owners and corporate medical directors prioritize capital investments in medical devices that automate clinical workflows, compress anesthesia induction and operative times, reduce physical monitoring burdens, and eliminate human calculation errors. Smart veterinary infusion pumps with pre-programmed drug libraries, multi-parameter vital signs monitors with automated arrhythmia detection algorithms, digital radiography suites that acquire diagnostic-grade exposures in seconds, and artificial intelligence-powered imaging triage tools are aggressively procured specifically to optimize workforce efficiency and mitigate clinical burnout.
Finally, the regulatory architecture governing companion animal medical devices in the United States fosters rapid product innovation and abbreviated commercialization cycles. The Center for Veterinary Medicine within the U.S. Food and Drug Administration does not require the exhaustive, multi-year Premarket Approval or 510(k) premarket notification clearance processes mandatory for human medical devices, provided the device does not emit radiation or cause adulteration and misbranding. While veterinary radiation-emitting devices such as X-ray systems, CT scanners, and fluoroscopy platforms remain subject to FDA Center for Devices and Radiological Health radiation safety standards, non-radiation veterinary surgical tools, monitoring platforms, orthopedic implants, and general consumables can transition from design freeze to commercial deployment far more rapidly than human medical devices. This agile regulatory environment enables manufacturers to iterate product designs, introduce advanced materials, and deploy responsive hardware updates at a fraction of human medtech development costs.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation across the U.S. companion animal medical devices market is centered on elevating clinical diagnostic precision, minimizing patient trauma through minimally invasive approaches, automating time-intensive workflows, and infusing software intelligence into physical hardware assets. Device manufacturers are moving beyond basic mechanical functionality, focusing instead on developing interconnected therapeutic and diagnostic platforms that interface smoothly with veterinary staff workflows and cloud-based data repositories.
Point-of-care ultrasound and handheld diagnostic imaging platforms embody this technological renaissance. Traditional veterinary ultrasound historically required bulky, expensive cart-based platforms confined to specialized radiology suites, requiring complex transducer adjustments and extensive operator expertise. Next-generation portable and ultra-lightweight handheld ultrasound systems utilize silicon-based capacitive micromachined ultrasound transducers and connect directly to commercial tablets and mobile interfaces. These platforms incorporate automated veterinary organ presets, artificial intelligence-assisted boundary detection for cardiac chambers, and guided focal point assessment for trauma protocols. General practitioners and emergency clinicians routinely utilize point-of-care ultrasound at the exam table to detect free abdominal fluid, pleural effusion, and gallbladder abnormalities within minutes of triage, democratizing advanced imaging beyond board-certified veterinary radiologists.
Veterinary orthopedic surgery has undergone a profound revolution through the integration of locking compression plate technology, 3D computer-aided surgical planning, and patient-specific 3D-printed titanium implants. Traditional non-locking dynamic compression plates relied exclusively on friction between the plate and cortical bone, frequently resulting in construct loosening, periosteal blood supply disruption, and fixation failure in osteopenic or active canine patients. Modern locking plate systems feature threaded screw holes that mechanically lock into the screw head, creating a rigid fixed-angle construct that preserves periosteal vascularity, accelerates cortical healing, and withstands elevated biomechanical stresses. Furthermore, for complex angular limb deformities, non-union fractures, and canine total hip or knee replacements, veterinary orthopedic manufacturers deploy computed tomography data into specialized software to fabricate custom-printed porous titanium implants and customized cutting guides, drastically reducing operative duration and post-surgical implant failure rates.
Minimally invasive surgery, encompassing veterinary laparoscopy, thoracoscopy, arthroscopy, and interventional endoscopy, is rapidly displacing open surgical techniques across both referral institutions and forward-looking general practices. Modern veterinary surgical towers combine ultra-high-definition 4K imaging, chip-on-the-tip digital video sensors, compact 3mm and 5mm instrumentation, and integrated light-emitting diode cold illumination sources engineered to navigate diminutive feline and canine abdominal cavities. Advanced bipolar electrosurgical generators and ultrasonic vessel sealing devices deliver rapid, vessel-ligation and tissue division for blood vessels up to 7mm in diameter without requiring foreign surgical clips or non-absorbable sutures. Laparoscopic prophylactic gastropexy, minimally invasive ovariectomy, and arthroscopic joint exploration are marketed directly to educated pet owners as premium surgical options that deliver reduced post-operative pain, negligible blood loss, minimal surgical site infection risks, and drastically accelerated recovery times.
Patient monitoring and veterinary anesthesia delivery platforms have similarly evolved from rudimentary analog displays into advanced, multi-parameter, software-driven life support ecosystems. Modern veterinary anesthesia machines feature precision multi-gas vaporization modules with automatic temperature and flow compensation, integrated ventilator displays capable of delivering pressure-regulated volume-controlled ventilation to feline patients weighing under two kilograms, and active waste gas scavenging mechanisms that safeguard clinic personnel. Concurrently, multi-parameter patient monitors incorporate specialized veterinary algorithms designed to accurately interpret high feline heart rates exceeding 250 beats per minute, low-perfusion states, and pediatric canine pulse waves. These monitors continuously synthesize electrocardiography, pulse oximetry, sidestream and microstream capnography, non-invasive oscillometric blood pressure, and core body temperature, transmitting continuous patient vitals directly to centralized nursing station monitors and integrated electronic medical record systems.
Artificial intelligence and cloud-connected tele-diagnostics represent the fastest-accelerating software layer integrated directly into companion animal medical hardware. Because the United States faces an acute shortage of board-certified veterinary radiologists, clinical practices often encounter delays of 24 to 72 hours when submitting digital radiographs for specialist over-read. In response, digital radiography hardware manufacturers are embedding deep-learning convolutional neural networks directly into image acquisition workstations. Within twenty to forty seconds of exposure, these artificial intelligence platforms screen images for acute abnormalities such as pulmonary nodules, cardiomegaly, pneumothorax, gastric dilatation-volvulus, intestinal foreign bodies, and osteolytic bone lesions. These algorithms serve as a critical diagnostic safety net for general practitioners during overnight shifts and emergency presentations, validating clinical decisions and optimizing patient stabilization workflows.
Segmentation Insights
The U.S. Companion Animal Medical Devices Market is segmented on the basis of product category, animal type, application / clinical indication, technology / modality type, and end user.
- By Product Category
Diagnostic Imaging Systems
Diagnostic imaging systems form the bedrock of clinical diagnosis, treatment planning, and surgical intervention across the veterinary ecosystem. In 2023, the U.S. companion animal diagnostic imaging systems segment stood at USD 0.88 billion, advancing to USD 0.98 billion in 2024, USD 1.09 billion in 2025, and reaching USD 1.22 billion in 2026. The segment is projected to attain USD 2.19 billion by 2032, expanding at a robust CAGR of 10.24% from 2027 to 2032. This performance is sustained by the indispensable role of cross-sectional and planar imaging in canine and feline clinical workups, combined with aggressive technological transitions toward direct digital radiography, high-resolution ultrasound, and low-dose veterinary computed tomography.
Veterinary ultrasound represents one of the most commercially resilient and widely deployed imaging modalities. System revenues across the United States reached USD 0.38 billion in 2023, expanding to USD 0.42 billion in 2024, USD 0.47 billion in 2025, and USD 0.53 billion in 2026, with projections targeting USD 0.97 billion by 2032. Cart-based ultrasound systems equipped with high-density linear, micro-convex, and phased array transducers dominate veterinary specialty referral centers, providing high spatial resolution for detailed feline abdominal assessments and canine echocardiography. Concurrently, ultra-portable handheld ultrasound units are experiencing explosive uptake in general community practices and emergency triage stations, allowing general practitioners to conduct rapid focused assessments with sonography for trauma, triage, and tracking at the exam table.
Digital radiography and dental X-ray systems represent a near-universal capital asset across U.S. companion animal clinics. The digital radiography and dental imaging subsegment registered USD 0.33 billion in 2023, rising to USD 0.36 billion in 2024, USD 0.40 billion in 2025, and USD 0.44 billion in 2026, on track to reach USD 0.77 billion by 2032. Flat-panel direct digital radiography detectors utilizing cesium iodide scintillators have almost completely supplanted older computed radiography cassette systems, dramatically curtailing patient exposure times, eliminating chemical processing, and yielding diagnostic-grade images in under four seconds. Veterinary dental radiography systems have mirrored this trajectory, driven by the clinical recognition that over 60% of canine and feline dental pathology resides subgingivally and cannot be diagnosed without intraoral digital radiography sensors.
Veterinary computed tomography and magnetic resonance imaging systems represent the fastest-growing subsegment within diagnostic imaging, moving from USD 0.17 billion in 2023 to USD 0.20 billion in 2024, USD 0.22 billion in 2025, and USD 0.25 billion in 2026, with expectations to reach USD 0.45 billion by 2032. Corporate specialty networks and large private multi-disciplinary hospitals increasingly treat multislice helical CT scanners (ranging from 16-slice to 128-slice configurations) as mandatory clinical infrastructure for oncologic staging, trauma assessment, complex fracture evaluation, and surgical planning. High-field 1.5-Tesla MRI systems engineered specifically for veterinary patients provide unmatched soft-tissue contrast resolution, underpinning the rapid expansion of veterinary neurology, neurosurgery, and musculoskeletal imaging services across the country.
Surgical & Operating Room Devices
Surgical and operating room devices represent a core driver of procedural revenue within U.S. veterinary facilities. This category generated USD 0.72 billion in 2023, expanding to USD 0.80 billion in 2024, USD 0.89 billion in 2025, and reaching USD 0.99 billion in 2026. The segment is projected to achieve USD 1.76 billion by 2032, progressing at a CAGR of 10.07% over the forecast period. The segment’s expansion is fueled by rising surgical procedure volumes, the broader adoption of minimally invasive laparoscopy, and the wholesale replacement of outdated manual surgical equipment with advanced energy platforms and precision instrumentation.
Veterinary electrosurgical units, radiofrequency generators, and advanced vessel-sealing platforms recorded USD 0.24 billion in 2023, advancing to USD 0.27 billion in 2024, USD 0.30 billion in 2025, and USD 0.34 billion in 2026, with expectations to touch USD 0.62 billion by 2032. Advanced bipolar vessel-sealing devices are widely procured by general and specialty veterinary hospitals because they fuse collagen and elastin in vascular walls to achieve permanent hemostasis in vessels up to 7mm without surgical ligatures. This capability dramatically accelerates routine procedures such as feline and canine ovariohysterectomies, splenectomies, and liver lobectomies while reducing intraoperative blood loss and general anesthesia duration.
Veterinary anesthesia delivery systems and active waste gas scavenging modules accounted for USD 0.22 billion in 2023, moving to USD 0.24 billion in 2024, USD 0.27 billion in 2025, and USD 0.30 billion in 2026, projected to surpass USD 0.52 billion by 2032. Given the inherent risks of general anesthesia in companion animals, modern veterinary practices invest in precision out-of-circuit vaporizers engineered for isoflurane and sevoflurane, integrated electronic ventilators with precision tidal volume delivery down to 5 milliliters for tiny pediatric and feline patients, and fail-safe oxygen supply alarms. Concurrently, regulatory scrutiny surrounding clinical staff exposure to halogenated waste anesthetic gases drives steady retrofitting of active scavenging systems and charcoal absorption devices across veterinary surgical suites.
Veterinary surgical hand instruments, ergonomic micro-surgical tools, and orthopedic power tool systems generated USD 0.26 billion in 2023, USD 0.29 billion in 2024, USD 0.32 billion in 2025, and USD 0.35 billion in 2026, climbing toward USD 0.62 billion by 2032. Surgical power equipment featuring autoclavable, brushless, lithium-ion battery-driven motors enables veterinary surgeons to oscillate, drill, and ream bone during complex orthopedic and neurosurgical procedures with exceptional tactile feedback and thermal control. Veterinary-specific surgical instrument sets crafted from high-tensile medical stainless steel and titanium resist wear through thousands of high-temperature autoclave sterilization cycles, maintaining mechanical precision across demanding procedural caseloads.
Patient Monitoring & Critical Care Devices
Patient monitoring and critical care equipment forms an indispensable safety layer across pre-operative, intra-operative, and post-operative veterinary care. The segment reached USD 0.60 billion in 2023, progressing to USD 0.66 billion in 2024, USD 0.73 billion in 2025, and USD 0.81 billion in 2026. The category is projected to reach USD 1.41 billion by 2032, exhibiting a CAGR of 9.68% from 2027 to 2032. The proliferation of multi-doctor practices, the expansion of 24-hour veterinary emergency hospitals, and heightened consumer expectations regarding surgical safety protocols sustain consistent procurement of vital signs monitors, infusion systems, and intensive care support hardware.
Multi-parameter veterinary patient monitors encompass the largest share of this segment, recording USD 0.28 billion in 2023, expanding to USD 0.31 billion in 2024, USD 0.34 billion in 2025, and USD 0.38 billion in 2026, on track to achieve USD 0.67 billion by 2032. Unlike repurposed human monitors that frequently misinterpret rapid quadruped heart rates and low peripheral vascular tone, dedicated veterinary monitors feature specialized firmware capable of measuring feline pulse rates up to 300 beats per minute, sidestream capnography adapted for low tidal volumes, continuous core body temperature probes, and multi-lead electrocardiography. The clinical trend involves deploying wireless, continuous telemetry monitors that stay attached to hospitalized patients in recovery wards, transmitting real-time physiological data to central monitoring screens and veterinary technician mobile tablets.
Veterinary infusion and syringe pumps generated USD 0.20 billion in 2023, advancing to USD 0.22 billion in 2024, USD 0.24 billion in 2025, and USD 0.27 billion in 2026, reaching an anticipated USD 0.47 billion by 2032. Accurate intravenous fluid therapy and micro-dose continuous drug infusions are essential for treating companion animal shock, dehydration, renal crisis, and intraoperative hypotension. Modern veterinary smart pumps incorporate extensive drug library profiles with hard and soft dosing limits for canine and feline patients, ultrasonic air-in-line detection, and pressure sensors that detect catheter occlusion or extravasation, mitigating clinical complications and technician monitoring burden.
Critical care ventilators, medical oxygen concentrators, and defibrillation/resuscitation devices generated USD 0.12 billion in 2023, rising to USD 0.13 billion in 2024, USD 0.15 billion in 2025, and USD 0.16 billion in 2026, targeting USD 0.27 billion by 2032. Veterinary intensive care units are investing in dedicated mechanical ventilators capable of delivering sophisticated lung-protective modes, synchronized intermittent mandatory ventilation, and high-flow nasal oxygen therapy to patients suffering from acute respiratory distress syndrome, pulmonary contusions, or congestive heart failure. Medical-grade on-site oxygen generation systems and emergency defibrillators further bolster clinical resilience in regional trauma centers.
Orthopedic & Prosthetic Implants
The orthopedic and prosthetic implants segment represents a specialized, high-margin domain that directly mirrors advanced human reconstructive surgery. The segment was valued at USD 0.44 billion in 2023, increasing to USD 0.49 billion in 2024, USD 0.54 billion in 2025, and USD 0.60 billion in 2026, with revenue forecast to reach USD 1.08 billion by 2032, demonstrating a CAGR of 10.28% during the forecast period. The primary clinical catalyst is the high incidence of cranial cruciate ligament ruptures, patellar luxations, severe fractures from vehicular trauma, hip dysplasia, and angular limb deformities in canine companions.
Tibial plateau leveling osteotomy plates, locking screw fixation sets, and trauma internal fixation systems constitute the largest portion of implant revenue, generating USD 0.26 billion in 2023, USD 0.29 billion in 2024, USD 0.32 billion in 2025, and USD 0.36 billion in 2026, projected to climb to USD 0.65 billion by 2032. Cranial cruciate ligament rupture is the single most prevalent canine orthopedic pathology in the United States, driving over one million stabilization procedures annually. Anatomically contoured, medical-grade titanium and 316L stainless steel TPLO plates featuring polyaxial locking screws provide exceptional biomechanical stability, eliminating postoperative limb casting and facilitating rapid bone consolidation.
Total joint replacement systems, comprising canine total hip, total knee, and total elbow replacement implants, generated USD 0.11 billion in 2023, advancing to USD 0.12 billion in 2024, USD 0.13 billion in 2025, and USD 0.15 billion in 2026, projected to reach USD 0.27 billion by 2032. As pet owners increasingly reject lifelong medical pain management for debilitating hip dysplasia, cementless and cemented total hip arthroplasty systems featuring micro-porous bone-ingrowth surfaces, cobalt-chrome femoral heads, and ultra-high-molecular-weight polyethylene acetabular cups are routinely performed across board-certified veterinary surgical centers.
Spinal implants, biomaterials, and customized 3D-printed orthopedic solutions accounted for USD 0.07 billion in 2023, USD 0.08 billion in 2024, USD 0.09 billion in 2025, and USD 0.09 billion in 2026, poised to achieve USD 0.16 billion by 2032. Veterinary neurosurgeons leverage specialized vertebral pedicle screws, locking spinal distraction plates, synthetic osteoconductive bone graft substitutes, and recombinant human bone morphogenetic proteins to stabilize spinal fractures and correct intervertebral disc herniations and cervical spondylomyelopathy (wobbler syndrome).
Consumables, Catheters & Wound Management
Consumables, catheters, and wound management products represent the recurring operational lifeblood of every companion animal practice. In 2023, this segment stood at USD 0.51 billion, expanding to USD 0.56 billion in 2024, USD 0.62 billion in 2025, and USD 0.68 billion in 2026. The segment is projected to attain USD 1.04 billion by 2032, expanding at a CAGR of 7.33% from 2027 to 2032. While capital equipment involves multi-year procurement cycles, consumables generate predictable, continuous, high-margin cash flows that scale directly with outpatient exam volume and surgical caseload.
Veterinary wound closure products, specialized sutures, and tissue adhesives generated USD 0.20 billion in 2023, moving to USD 0.22 billion in 2024, USD 0.24 billion in 2025, and USD 0.26 billion in 2026, projected to reach USD 0.40 billion by 2032. Synthetic absorbable braided and monofilament sutures, non-absorbable polymers, and antimicrobial-coated suture strands are utilized in massive volumes for general soft-tissue apposition, abdominal closures, and subcutaneous reconstruction. Veterinary surgical practices also utilize topical veterinary skin staples, surgical hemoclips, and medical-grade cyanoacrylate tissue adhesives to achieve rapid closure in trauma emergencies and high-tension cutaneal lacerations.
Intravenous access catheters, fluid delivery administration sets, and specialized drainage tubes recorded USD 0.17 billion in 2023, USD 0.19 billion in 2024, USD 0.21 billion in 2025, and USD 0.23 billion in 2026, climbing to USD 0.36 billion by 2032. Over-the-needle peripheral intravenous catheters engineered with radiopaque polyurethane tubing and safety-shielded needle retraction systems represent a standard disposable used across every hospitalized patient. Furthermore, central venous catheters, peripherally inserted central catheters, thoracic chest tubes, and silicone urinary drainage systems represent steady consumable requirements within emergency and intensive care departments.
Advanced wound dressings, antimicrobial bandages, negative pressure wound therapy consumables, and endotracheal tubes generated USD 0.14 billion in 2023, advancing to USD 0.15 billion in 2024, USD 0.17 billion in 2025, and USD 0.19 billion in 2026, forecast to attain USD 0.28 billion by 2032. Companion animals frequently present with extensive soft-tissue trauma, bite wounds, degloving injuries, and decubital ulcers that require moisture-retentive hydrocolloids, medical-grade honey dressings, silver-impregnated barrier wraps, and portable negative-pressure suction sponges to accelerate granulation tissue formation and wound contracture.
- By Animal Type
Canine (Dogs)
The canine segment represents the largest and most lucrative animal type within the U.S. companion animal medical devices market. Canine care accounted for USD 2.14 billion in 2023, progressing to USD 2.37 billion in 2024, USD 2.62 billion in 2025, and reaching USD 2.90 billion in 2026. The canine category is forecast to achieve USD 5.12 billion by 2032, advancing at a CAGR of 9.94% during the forecast period. The demographic dominance of dogs, with an estimated population exceeding 85 million across American households, combined with their elevated susceptibility to traumatic injuries, severe degenerative joint disease, complex cardiac conditions, and diverse neoplasms, establishes canines as the primary consumers of diagnostic imaging, orthopedic reconstruction, and advanced surgical interventions.
U.S. dog owners demonstrate an extraordinary propensity to authorize advanced medical expenditures, driven by deep human-canine bonding and higher pet insurance enrollment relative to other species. Over 80% of all veterinary orthopedic surgical procedures performed in the United States, including cranial cruciate ligament repairs, total hip replacements, and spinal decompressive procedures, are performed on canine patients. Furthermore, canine anatomy accommodates a broader spectrum of diagnostic modalities and surgical instrumentation adapted from human medicine, enabling the immediate deployment of standard human laparoscopes, high-definition endoscopes, orthopedic power tools, and vascular catheters with minimal dimensional modification.
Feline (Cats)
The feline segment represents an increasingly sophisticated, high-growth sector within companion animal medicine. Feline medical device spending stood at USD 0.76 billion in 2023, advancing to USD 0.84 billion in 2024, USD 0.93 billion in 2025, and USD 1.03 billion in 2026. The segment is projected to achieve USD 1.83 billion by 2032, expanding at a CAGR of 10.05% from 2027 to 2032. While cats have historically suffered from lower clinical visit frequencies compared to dogs due to carrier stress and subtle disease manifestation, veterinary industry initiatives such as “Cat Friendly Practice” certifications have successfully driven feline healthcare utilization across the United States.
Cats possess distinct physiological and anatomical characteristics that demand specialized, miniaturized medical devices. Geriatric felines exhibit high prevalence rates of chronic kidney disease, feline idiopathic cystitis, ureteral obstructions, diabetes mellitus, hypertrophic cardiomyopathy, and severe periodontal resorptive lesions. Consequently, veterinary device manufacturers have developed feline-specific micro-infusion sets, ultra-fine 24- and 26-gauge intravenous catheters, specialized low-dead-space capnography sensors, micro-endoscopes, and microvascular surgical instruments. Interventional procedures such as feline subcutaneous ureteral bypass system placements have emerged as routine life-saving interventions in referral centers, driving procurement of specialized fluoroscopic imaging, micro-guidewires, and silicone catheter assemblies.
Equine (Horses)
The equine medical device segment represents a highly capitalized specialty niche focused predominantly on performance athletes, breeding stock, and pleasure horses. Valued at USD 0.19 billion in 2023, the segment expanded to USD 0.21 billion in 2024, USD 0.23 billion in 2025, and USD 0.25 billion in 2026, with long-term forecasts targeting USD 0.40 billion by 2032, reflecting a CAGR of 8.16% between 2027 and 2032. Although smaller in aggregate animal census than canine or feline populations, equine medicine involves exceptionally high capital expenditure per animal, driven by the significant economic value of sport horses participating in racing, show jumping, dressage, and Western performance disciplines.
Equine veterinary practices require rugged, heavy-duty, highly portable diagnostic and surgical technologies. Equine ambulatory practitioners utilize specialized battery-powered portable digital radiography units, ultra-rugged field ultrasound platforms for musculoskeletal tendon and reproductive evaluation, and high-powered shockwave therapy systems directly at the stable or racetrack. Equine surgical referral hospitals invest heavily in large-bore standing computed tomography scanners, robotic-arm cone-beam CT systems capable of imaging the head and limbs of standing sedated horses, high-field open MRI platforms, and specialized large-animal hydraulic surgical tables and gas anesthesia machines capable of supporting equine body weights exceeding 500 kilograms.
Other Companion Animals (Avian, Exotic, Small Mammals)
The exotic and small companion animal segment encompasses avian species, reptiles, rabbits, ferrets, guinea pigs, and other small pocket mammals. This segment recorded USD 0.06 billion in 2023, moving to USD 0.06 billion in 2024, USD 0.07 billion in 2025, and USD 0.08 billion in 2026, projected to attain USD 0.13 billion by 2032, progressing at a CAGR of 8.44% during the forecast period. While historically considered a marginal clinical niche, ownership of exotic pets has expanded among suburban and urban millennial households, creating a specialized clinical ecosystem demanding adapted micro-medical instrumentation.
Exotic companion animal medicine presents severe clinical challenges related to patient size, rapid metabolic rates, and high vulnerability to hypothermia during anesthesia. Device utilization within exotic practices centers on precision diagnostic and therapeutic micro-instruments, including ultra-fine 1mm to 2.7mm rigid endoscopes for avian coelioscopy, micro-dental burs for lagomorph malocclusion management, precision microsurgical forceps, Doppler blood pressure monitors capable of detecting faint peripheral flow, active warm-air patient warming blankets, and pediatric incubation cages with integrated oxygen concentrators and digital humidity regulation.
- By Application / Clinical Indication
Orthopedics & Traumatology
Orthopedics and traumatology represents the single most commercially valuable clinical application segment within the U.S. companion animal medical devices market. The segment generated USD 0.98 billion in 2023, rising to USD 1.08 billion in 2024, USD 1.20 billion in 2025, and USD 1.33 billion in 2026, with revenues projected to reach USD 2.37 billion by 2032, expanding at a CAGR of 10.12% from 2027 to 2032. The market expansion is sustained by the heavy caseload of orthopedic trauma, vehicular accidents, congenital bone deformities, and chronic degenerative joint disease in active and aging canine breeds.
Clinical demand within this application is dominated by surgical stabilization systems for canine cranial cruciate ligament disease, which represents the most frequently performed orthopedic surgery in veterinary medicine. TPLO and tibial tuberosity advancement systems, locking compression fracture plates, external skeletal fixation frames, and total joint replacement implants generate immense device revenue. Veterinary orthopedic surgeons utilize advanced intraoperative fluoroscopy, surgical power drills, specialized osteotomes, and bone-morphogenetic graft biomaterials to achieve structural stabilization, rapid bone healing, and early post-operative limb loading.
Soft Tissue Surgery & Laparoscopy
Soft tissue surgery and minimally invasive laparoscopy accounted for USD 0.79 billion in 2023, expanding to USD 0.87 billion in 2024, USD 0.96 billion in 2025, and USD 1.07 billion in 2026, on track to reach USD 1.91 billion by 2032, exhibiting a CAGR of 10.11% between 2027 and 2032. Soft tissue procedures represent the highest-frequency surgical caseload across both general practices and referral hospitals, encompassing routine gonadectomies, gastrointestinal foreign body removals, exploratory laparotomies, splenectomies, cystotomies, and oncologic tumor resections.
The rapid migration from traditional open laparotomy toward minimally invasive laparoscopy and thoracoscopy represents a defining growth vector. Veterinary practices invest heavily in laparoscopic surgical towers, carbon dioxide insufflators, 5mm optical trocars, and advanced bipolar vessel sealers. Laparoscopic procedures reduce surgical trauma, decrease post-operative analgesia requirements, minimize infection risks, and drastically shorten patient hospitalization, making these techniques highly attractive to pet owners who view minimally invasive approaches as the gold standard of contemporary surgical care.
Cardiology & Emergency/Critical Care
Cardiology, emergency, and critical care applications generated USD 0.54 billion in 2023, advancing to USD 0.59 billion in 2024, USD 0.65 billion in 2025, and USD 0.72 billion in 2026, projected to attain USD 1.28 billion by 2032, growing at a CAGR of 10.07% over the forecast period. The rising prevalence of degenerative mitral valve disease, dilated cardiomyopathy, congestive heart failure, and acute traumatic emergencies drives continuous utilization of diagnostic, monitoring, and life-support platforms across 24-hour veterinary emergency networks.
Specialized device deployment in this sector includes high-end echocardiography systems equipped with continuous-wave and tissue Doppler imaging, telemetry units for continuous arrhythmia screening, automated external defibrillators, blood gas and electrolyte analyzers, and specialized veterinary mechanical ventilators. Furthermore, interventional veterinary cardiology has emerged as a distinct specialty, driving procurement of vascular access sheaths, balloon valvuloplasty catheters, and transcatheter occlusion devices for congenital defects such as patent ductus arteriosus and pulmonic stenosis.
Neurology & Neurosurgery
Neurology and neurosurgery generated USD 0.28 billion in 2023, rising to USD 0.31 billion in 2024, USD 0.35 billion in 2025, and USD 0.38 billion in 2026, forecast to achieve USD 0.69 billion by 2032, expanding at a CAGR of 10.45% from 2027 to 2032. This represents one of the fastest-growing specialty application segments, propelled by the high incidence of intervertebral disc disease in chondrodystrophic dog breeds (such as Dachshunds, French Bulldogs, and Corgis), spinal fractures, traumatic brain injuries, and intracranial neoplasms.
Veterinary neurosurgical suites require substantial capital investments, including high-field 1.5T MRI systems, multi-slice CT scanners, operating microscopes, ultrasonic surgical aspirators for delicate tumor debulking, pneumatic high-speed neurosurgical burrs, and specialized spinal fixation hardware. As board-certified veterinary neurologists expand across corporate referral hospitals, neurosurgical interventions that restore mobility and eliminate chronic neurologic pain are increasingly performed with exceptional clinical success.
Dentistry & Ophthalmic Procedures
Dentistry and ophthalmic applications recorded USD 0.35 billion in 2023, progressing to USD 0.38 billion in 2024, USD 0.42 billion in 2025, and USD 0.47 billion in 2026, climbing toward USD 0.78 billion by 2032, reflecting an 8.82% CAGR during the forecast period. Periodontal disease represents the single most widespread infectious pathology diagnosed in companion animal medicine, affecting over 80% of dogs and 70% of cats by three years of age.
Veterinary dental suites represent a standardized revenue center in virtually every community practice, utilizing dedicated mobile dental delivery carts equipped with high-speed water-cooled handpieces, piezoelectric ultrasonic scalers, low-speed polishing contra-angles, and digital dental radiography sensors. Concurrently, veterinary ophthalmology utilizes specialized operating microscopes, phacoemulsification units for canine cataract removal, indirect ophthalmoscopes, and rebound tonometers for glaucoma screening, delivering advanced microsurgical restoration of vision.
General Diagnostics & Preventive Medicine
General diagnostics and preventive medicine applications generated USD 0.21 billion in 2023, advancing to USD 0.25 billion in 2024, USD 0.27 billion in 2025, and USD 0.29 billion in 2026, projected to touch USD 0.45 billion by 2032, expanding at a CAGR of 7.58% between 2027 and 2032. This segment encompasses the foundational hardware and screening devices deployed during routine wellness examinations, pre-anesthetic clearances, and preventive care visits across general veterinary clinics.
Device utilization within preventive care includes point-of-care blood chemistry and hematology analyzers, benchtop urinalysis platforms, basic hand-held diagnostic ophthalmoscopes and otoscopes, electronic digital stethoscopes with phonocardiogram visualization, and automated non-invasive blood pressure monitors. The emphasis on early chronic disease detection and proactive wellness monitoring ensures steady consumable turnover and predictable hardware replacement cycles across primary care veterinary practices.
- By Technology / Modality Type
Capital & Standalone Hardware Systems
Capital and standalone hardware systems form the largest revenue-generating technology segment, accounting for USD 1.54 billion in 2023, expanding to USD 1.70 billion in 2024, USD 1.88 billion in 2025, and USD 2.08 billion in 2026. The segment is projected to achieve USD 3.66 billion by 2032, expanding at a CAGR of 9.87% from 2027 to 2032. This technology classification includes major multi-year practice investments such as fixed digital radiography suites, cart-based color Doppler ultrasound machines, computed tomography scanners, high-field MRI units, veterinary anesthesia workstations, rigid laparoscopy towers, and surgical operating microscopes.
Procurement of capital equipment in the companion animal space is governed by clear financial return-on-investment timelines and workflow integration. While human hospitals rely on complex bureaucratic procurement committees and public bond financing, veterinary practice owners and corporate regional directors evaluate capital hardware based on procedure billing rates, client fee acceptance, technician ease-of-use, and service contract coverage. Leading capital equipment manufacturers pair physical hardware sales with multi-year comprehensive warranty programs, preventive maintenance schedules, and continuous software updates, creating reliable recurring service revenue alongside initial hardware placements.
Point-of-Care & Mobile/Handheld Devices
Point-of-care and mobile handheld devices represent an exceptionally dynamic, high-growth technology segment. The segment was valued at USD 0.54 billion in 2023, moving to USD 0.60 billion in 2024, USD 0.66 billion in 2025, and USD 0.73 billion in 2026, projected to attain USD 1.34 billion by 2032, exhibiting a CAGR of 10.65% from 2027 to 2032. The demand for decentralized diagnostic testing, rapid bedside patient triage, and mobile veterinary house-call services has propelled rapid adoption of compact, battery-powered medical platforms.
This technology group encompasses handheld point-of-care ultrasound transducers that beam live imaging directly to smartphones and tablets, wireless patient vital signs monitors, handheld tonometers, mobile blood gas analyzers, and portable veterinary digital X-ray generators. Point-of-care platforms eliminate the operational delays associated with transferring unstable patients to dedicated imaging or laboratory rooms, enabling immediate clinical triage at the exam table or in emergency cages, while dramatically lowering the capital entry barrier for newly established or mobile veterinary clinics.
Software-Integrated & Cloud-Connected Platforms
Software-integrated and cloud-connected platforms represent the fastest-accelerating technology segment in the market. Valued at USD 0.32 billion in 2023, this segment rose to USD 0.36 billion in 2024, USD 0.40 billion in 2025, and USD 0.45 billion in 2026, forecast to achieve USD 0.90 billion by 2032, advancing at a rapid CAGR of 12.26% over the forecast period. The convergence of physical medical hardware with cloud-based software architectures, artificial intelligence diagnostic algorithms, and centralized tele-consultation networks is redefining medtech value propositions.
Hardware devices such as digital radiography stations, multi-parameter monitors, and smart infusion pumps are increasingly sold as interconnected digital endpoints that feed real-time patient data directly into cloud-based veterinary PACS and practice management software systems. Integrated deep-learning algorithms automatically screen radiological exposures for acute abnormalities, verify correct patient positioning, and flag subtle pulmonary or skeletal lesions within seconds. Furthermore, continuous tele-monitoring platforms allow off-site veterinary criticalists and board-certified specialists to supervise intensive care patient parameters remotely across dozens of satellite clinics, expanding specialist care access and creating profitable software-as-a-service subscription streams for medtech vendors.
Implantable Systems & Biomaterials
Implantable systems and biomaterials recorded USD 0.28 billion in 2023, expanding to USD 0.31 billion in 2024, USD 0.35 billion in 2025, and USD 0.39 billion in 2026, climbing toward USD 0.70 billion by 2032, reflecting a CAGR of 10.22% during the forecast period. This technology category encompasses permanent and semi-permanent internal fixation hardware, prosthetic joint components, spinal stabilization assemblies, synthetic bone graft matrices, and implantable cardiovascular devices.
Technological progress within this segment is defined by advanced material science, including the widespread deployment of grade-5 titanium alloys, polyetheretherketone (PEEK) spinal spacers, bioabsorbable fixation pins, and porous 3D-printed metal constructs that promote rapid osseointegration. Manufacturers collaborate closely with academic veterinary institutions and board-certified orthopedic surgeons to engineer biomechanically validated implants that match the unique torsional and compressive loading environments of quadruped quad-limbed locomotion, ensuring structural longevity and minimizing implant fatigue failure.
Single-Use Disposable & Reusable Consumables
Single-use disposable and reusable consumables generated USD 0.47 billion in 2023, progressing to USD 0.51 billion in 2024, USD 0.56 billion in 2025, and USD 0.61 billion in 2026, projected to attain USD 0.88 billion by 2032, registering a CAGR of 6.29% between 2027 and 2032. Consumable devices include surgical suture packs, intravenous catheters, fluid administration lines, disposable capnography airway adapters, electrosurgical pencil blades, advanced wound dressings, and endotracheal tubes.
The commercial dynamics of the consumables category are anchored in high-volume, repeat purchasing and strict infection control standards. As veterinary clinics adopt higher hygiene standards to prevent hospital-acquired infections, particularly in intensive care units and orthopedic operating rooms, the utilization of sterile single-use disposable products has largely superseded older manual re-sterilization practices. Manufacturers optimize supply-chain distribution agreements and practice management software inventory integrations to ensure automated, friction-free replenishment of high-turnover clinical consumables.
- By End User
Veterinary Hospitals & Multi-Specialty Referral Centers
Veterinary hospitals and multi-specialty referral centers represent the largest end-user category, accounting for USD 1.83 billion in 2023, expanding to USD 2.03 billion in 2024, USD 2.25 billion in 2025, and USD 2.50 billion in 2026. The segment is projected to attain USD 4.54 billion by 2032, expanding at a CAGR of 10.45% from 2027 to 2032. These advanced referral institutions, which house board-certified specialists across surgery, internal medicine, neurology, oncology, cardiology, and emergency/critical care, serve as the primary purchasers of top-tier capital medical equipment.
A single multi-specialty veterinary hospital often operates multiple dedicated surgical operating suites, an advanced imaging pavilion equipped with 64-slice CT and 1.5T MRI scanners, a fluoroscopy suite, a continuous-monitoring intensive care unit, and dedicated endoscopy suites. Capital procurement within these centers is driven by procedural complexity, equipment reliability, high patient throughput capacity, and compatibility with advanced specialty training programs. These hospitals invest continuously in cutting-edge surgical power systems, advanced energy vessel sealers, interventional radiology catheters, and mechanical ventilators to manage the most acute, complex caseloads referred by regional community clinics.
Private Veterinary Clinics & Community Practices
Private veterinary clinics and community practices generated USD 0.69 billion in 2023, advancing to USD 0.76 billion in 2024, USD 0.84 billion in 2025, and USD 0.92 billion in 2026, projected to reach USD 1.54 billion by 2032, exhibiting a CAGR of 8.97% between 2027 and 2032. Independent community practices form the geographical foundation of companion animal healthcare across the United States, providing primary wellness examinations, preventive medicine, routine soft-tissue surgeries (such as spays, neuters, and mass removals), and baseline dental care.
Device procurement within independent practices is characterized by a strong focus on cost-effectiveness, versatility, compact physical footprint, and rapid operational return on investment. Practice owners favor multi-functional platforms, such as combination vital signs monitors that integrate capnography, ECG, and blood pressure into a single portable housing, benchtop dental delivery units with integrated ultrasonic scalers, and digital radiography retrofits that utilize existing X-ray tables. As independent clinics face competition from corporate consolidators, many invest selectively in point-of-care ultrasound and advanced dental radiography to retain diagnostic and surgical revenue in-house.
Corporate Veterinary Chains & Consolidators
Corporate veterinary chains and consolidator management organizations generated USD 0.41 billion in 2023, rising to USD 0.46 billion in 2024, USD 0.51 billion in 2025, and USD 0.57 billion in 2026, on track to achieve USD 0.97 billion by 2032, reflecting a CAGR of 9.27% during the forecast period. The rapid corporatization of the U.S. veterinary market has consolidated purchasing power into major regional and national networks that manage hundreds to thousands of primary care and specialty veterinary clinics.
Corporate consolidators leverage enterprise-level procurement contracts, standardizing medical device brands across their entire clinic portfolios to secure substantial volume discounts, streamline staff onboarding, and establish uniform clinical protocols. Enterprise device procurement decisions involve centralized corporate medical leadership, supply chain directors, and financial analysts who evaluate equipment based on total cost of ownership, mean time between failures, fleet-wide service level agreements, and data interoperability across centralized cloud practice management architectures.
Academic Veterinary Institutions & Research Centers
Academic veterinary institutions and research centers recorded USD 0.16 billion in 2023, moving to USD 0.17 billion in 2024, USD 0.19 billion in 2025, and USD 0.20 billion in 2026, projected to attain USD 0.32 billion by 2032, progressing at a CAGR of 8.16% from 2027 to 2032. The thirty-three accredited veterinary medical colleges across the United States, along with private veterinary translational research foundations, serve as the clinical proving grounds and educational hubs for the next generation of veterinary surgeons and specialists.
Academic teaching hospitals operate as the most technologically advanced veterinary facilities in the world, routinely procuring experimental, specialized, and human-grade medtech platforms that exceed the budgetary capabilities of private clinics. Academic veterinary medical centers invest in stereotactic linear accelerators, high-field 3.0T research MRI scanners, robotic-assisted surgical platforms, intraoperative neuro-monitoring systems, and advanced cardiopulmonary bypass circuits. Furthermore, academic clinical trials evaluate novel implants, regenerative biomaterials, and advanced interventional techniques, generating published peer-reviewed evidence that steers subsequent commercial device adoption across the broader private veterinary sector.
Ambulatory & Mobile Veterinary Services
Ambulatory and mobile veterinary services generated USD 0.06 billion in 2023, advancing to USD 0.06 billion in 2024, USD 0.07 billion in 2025, and USD 0.08 billion in 2026, forecast to reach USD 0.12 billion by 2032, reflecting a CAGR of 6.99% between 2027 and 2032. The popularity of at-home veterinary care, mobile surgical and dental vans, and ambulatory equine practices has expanded steadily, driven by pet owner demand for low-stress veterinary visits and convenient home-based clinical management.
Ambulatory veterinary practitioners require exceptionally durable, battery-operated, lightweight, and weather-resistant medical equipment. Procurement focuses on ultra-portable handheld ultrasound wands, battery-driven handheld digital X-ray generators with wireless flat-panel detectors, portable dental delivery suitcases, mobile blood chemistry and electrolyte benchtop analyzers, and compact vital signs monitoring monitors. These devices enable practitioners to deliver comprehensive diagnostic examinations, basic dental scalings, and minor surgical procedures directly within customized mobile vans or client residences.
Regional Insights: Where the Market is Growing Fastest
The U.S. Companion Animal Medical Devices Market is geographically segmented into the South, Northeast, Midwest, and West. Regional device consumption exhibits pronounced variation driven by total companion pet census, regional household income demographics, pet health insurance penetration rates, specialty veterinary referral hospital density, corporate consolidation activity, climate-related disease vectors, and equine performance industry concentration.
The South represents the largest overall commercial marketplace for companion animal medical devices, driven by massive pet populations, rapid sunbelt demographic expansion, and substantial hospital construction. The West represents the most technologically advanced and fastest-growing regional market, propelled by high disposable incomes, progressive animal welfare sentiment, and rapid adoption of connected veterinary digital platforms. The Northeast is characterized by an exceptionally dense concentration of premier academic veterinary institutions and specialty referral hospitals that drive premium per-procedure device spending. The Midwest provides a highly stable, commercially significant foundation anchored by large suburban pet populations, premier veterinary colleges, and expansive agricultural and sporting equine centers.
South
The South generated USD 1.10 billion in 2023, expanding to USD 1.22 billion in 2024, USD 1.35 billion in 2025, and USD 1.49 billion in 2026. The region is forecast to achieve USD 2.66 billion by 2032, expanding at a CAGR of 10.15% during the forecast period. The South represents the largest geographical revenue contributor, capturing approximately 35.0% of total U.S. companion animal medical device expenditure in 2026. This dominance is underpinned by favorable demographic trends, including rapid human population migration to Sunbelt states, expansive suburban homeownership that correlates directly with multi-pet households, high concentrations of sporting and hunting canine breeds, and lower operational overhead that encourages large-scale veterinary hospital construction.
Texas stands as the undisputed commercial anchor of the Southern market and ranks among the two largest individual state markets in the country. The state’s companion animal medical device market reached USD 0.42 billion in 2026, progressing steadily from USD 0.31 billion in 2023, USD 0.34 billion in 2024, and USD 0.38 billion in 2025, with expectations to attain USD 0.76 billion by 2032. Texas is home to more than 7.2 million pet-owning households, supporting dense clusters of multi-specialty referral networks and 24-hour emergency hospitals across the Houston, Dallas-Fort Worth, Austin, and San Antonio metropolitan areas. The state features exceptional capital expenditure in advanced orthopedic internal fixation systems, advanced vessel-sealing laparoscopy units, and standing equine computed tomography systems, the latter driven by major equine breeding and performance centers throughout North Texas. Academic centers such as Texas A&M University College of Veterinary Medicine drive high-end clinical adoption of 3.0T MRI, stereotactic radiation planning systems, and complex interventional cardiology devices.
Florida represents the second-largest market within the South, recording USD 0.34 billion in 2026, following historical valuations of USD 0.25 billion in 2023, USD 0.28 billion in 2024, and USD 0.31 billion in 2025, projected to achieve USD 0.61 billion by 2032. Florida’s companion animal healthcare market benefits from substantial affluent retiree demographics who treat companion pets as primary companions, resulting in high authorization rates for complex geriatric oncology, cardiology, and ophthalmic procedures. The South Florida corridor (Miami-Fort Lauderdale-West Palm Beach), along with the Tampa-St. Petersburg and Orlando metropolitan regions, supports an extensive private veterinary specialty infrastructure. Florida practices exhibit exceptionally high per-clinic adoption of color Doppler echocardiography, phacoemulsification units for cataract extractions, and multi-parameter vital signs monitors. Furthermore, Ocala and Wellington represent global centers of equestrian sport, generating massive recurring procurement of portable digital radiography, high-frequency regenerative shockwave therapy devices, and advanced musculoskeletal ultrasound systems.
North Carolina generated USD 0.16 billion in 2026, advancing from USD 0.12 billion in 2023, USD 0.13 billion in 2024, and USD 0.15 billion in 2025, on track to touch USD 0.29 billion by 2032. The state’s veterinary market is heavily catalyzed by the Research Triangle (Raleigh-Durham-Chapel Hill) and the Charlotte metropolitan area, characterized by high household incomes, booming suburban communities, and high pet insurance adoption. North Carolina State University College of Veterinary Medicine is globally recognized for veterinary clinical innovation, pioneering clinical trials in canine neurosurgery, 3D-printed titanium bone scaffolds, and interventional radiology. Community practices across the state demonstrate strong capital procurement rates for direct digital radiography retrofits, high-speed dental delivery stations, and smart veterinary infusion pumps.
Georgia accounted for USD 0.15 billion in 2026, moving from USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.14 billion in 2025, with forecasts projecting USD 0.27 billion by 2032. Growth is anchored by the sprawling Atlanta metropolitan area, which houses numerous 24-hour emergency centers and multi-disciplinary referral hospitals operated by corporate consolidators. Georgia veterinary clinics exhibit high caseloads of canine heartworm disease, trauma, and orthopedic conditions, driving sustained consumption of vascular access catheters, diagnostic point-of-care ultrasound units, and TPLO locking plate implants. The University of Georgia College of Veterinary Medicine in Athens provides additional academic impetus, continuously investing in advanced imaging and soft-tissue surgical towers.
Virginia recorded USD 0.13 billion in 2026, rising from USD 0.10 billion in 2023, USD 0.11 billion in 2024, and USD 0.12 billion in 2025, on pace to reach USD 0.24 billion by 2032. Northern Virginia, representing an affluent suburban extension of the Washington, D.C. metropolitan area, displays some of the highest per-capita expenditures on specialized pet healthcare in the nation. Practice owners in this corridor invest heavily in advanced diagnostic imaging modalities, including dedicated veterinary helical CT scanners, high-resolution endoscopy towers, and wireless vital signs monitoring systems. Additional Southern states, including Tennessee, Maryland, South Carolina, Alabama, Louisiana, Kentucky, Oklahoma, and Arkansas, collectively contributed USD 0.29 billion in 2026 and are projected to reach USD 0.50 billion by 2032. These markets support a robust blend of suburban companion animal practices, university teaching hospitals (such as Auburn University, University of Tennessee, and Louisiana State University), and equine sport medicine centers, sustaining stable procurement of anesthesia machines, general surgical power tools, and high-turnover disposable surgical consumables.
West
The West generated USD 0.85 billion in 2023, advancing to USD 0.94 billion in 2024, USD 1.04 billion in 2025, and USD 1.15 billion in 2026. The region is projected to reach USD 2.06 billion by 2032, expanding at a CAGR of 10.20% during the forecast period. Capturing approximately 27.0% of total U.S. market value in 2026, the West represents the fastest-growing geographical region in the nation. The Western market is defined by progressive animal welfare sensibilities, high per-capita pet expenditures, early adoption of novel medtech platforms, and the nation’s highest concentration of enrolled pet health insurance policies.
California dominates the West and stands as the single largest state market for companion animal medical devices in the United States, recording USD 0.58 billion in 2026, following historical valuations of USD 0.43 billion in 2023, USD 0.48 billion in 2024, and USD 0.53 billion in 2025, projected to surpass USD 1.05 billion by 2032. California represents an economic juggernaut characterized by an enormous pet population, exceptional household wealth in major coastal metropolitan centers, and a consumer base that routinely demands human-grade medical treatment for their pets. The Greater Los Angeles Basin, San Francisco Bay Area, San Diego County, and Orange County support the highest density of private veterinary specialty referral hospitals, veterinary oncologic centers, and 24-hour emergency practices in North America.
California veterinary practices serve as the primary test market for cutting-edge technologies, including artificial intelligence-assisted digital radiography, chip-on-the-tip 4K video laparoscopy towers, minimally invasive feline subcutaneous ureteral bypass systems, and customized 3D-printed orthopedic implants. The presence of world-leading academic centers, notably the University of California, Davis School of Veterinary Medicine and Western University of Health Sciences, provides clinical leadership in veterinary cardiopulmonary bypass, hemodialysis, advanced neurosurgery, and regenerative stem cell therapies, catalyzing downstream device procurement throughout the state’s expansive corporate and independent veterinary network.
Washington recorded USD 0.14 billion in 2026, moving from USD 0.10 billion in 2023, USD 0.11 billion in 2024, and USD 0.13 billion in 2025, projected to attain USD 0.26 billion by 2032. Growth is intensely concentrated within the Greater Seattle-Bellevue-Tacoma metropolitan region, where high median household incomes, thriving technology workforces, and exceptionally high pet ownership rates stimulate the market. Washington pet owners demonstrate high rates of pet health insurance enrollment, facilitating routine deployment of advanced diagnostic workups, helical CT imaging, and complex orthopedic fracture repairs. Washington State University College of Veterinary Medicine in Pullman further enriches the regional ecosystem through ongoing investments in advanced orthopedic power tools, fluoroscopy units, and critical care monitoring systems.
Colorado accounted for USD 0.13 billion in 2026, rising from USD 0.09 billion in 2023, USD 0.11 billion in 2024, and USD 0.12 billion in 2025, on track to reach USD 0.23 billion by 2032. Colorado features one of the most active, outdoor-oriented canine populations in the United States, which directly correlates with an extraordinary clinical caseload of canine cranial cruciate ligament ruptures, joint trauma, and athletic musculoskeletal injuries. Consequently, veterinary practices across the Denver, Boulder, Fort Collins, and Colorado Springs corridors exhibit high per-clinic adoption of TPLO locking plates, total joint replacement systems, musculoskeletal ultrasound transducers, and surgical arthroscopy towers. Colorado State University College of Veterinary Medicine and Biomedical Sciences, internationally renowned for its Flint Animal Cancer Center and orthopedic research programs, maintains unmatched capital device assets and frequently pioneers interventional oncologic and orthopedic device evaluations.
Arizona generated USD 0.11 billion in 2026, advancing from USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025, with expectations to achieve USD 0.20 billion by 2032. Population migration toward the Phoenix-Mesa-Scottsdale and Tucson metropolitan centers has catalyzed extensive construction of modern, large-format companion animal emergency hospitals and private practices. The state’s dry, desert climate and year-round outdoor lifestyle contribute to unique trauma and environmental emergency presentations, driving steady procurement of multi-parameter monitoring stations, point-of-care ultrasound systems, and veterinary intensive care oxygen delivery equipment.
Oregon recorded USD 0.08 billion in 2026, moving from USD 0.06 billion in 2023, USD 0.07 billion in 2024, and USD 0.07 billion in 2025, forecast to reach USD 0.14 billion by 2032. The Portland metropolitan region represents a progressive, pet-centric market with strong consumer preference for minimally invasive surgical techniques, low-stress veterinary handling, and advanced preventive dentistry. The remainder of the Western region, including Nevada, Utah, Idaho, Hawaii, Alaska, Montana, and Wyoming, collectively generated USD 0.11 billion in 2026 and is on track to touch USD 0.19 billion by 2032. These states combine fast-growing suburban hubs (such as Las Vegas, Salt Lake City, and Boise) with vast rural and mountain territories, stimulating demand for durable mobile diagnostic imaging platforms, portable orthopedic power equipment, and rugged emergency medical devices.
Midwest
The Midwest accounted for USD 0.63 billion in 2023, advancing to USD 0.70 billion in 2024, USD 0.77 billion in 2025, and USD 0.85 billion in 2026. The region is forecast to achieve USD 1.47 billion by 2032, expanding at a CAGR of 9.57% during the forecast period. Representing approximately 20.0% of total U.S. market value in 2026, the Midwest is characterized by high rates of homeownership, an expansive population of medium-to-large canine breeds, an established base of multi-doctor independent veterinary practices, and an unparalleled concentration of elite veterinary academic medical institutions.
Illinois represents the premier state market within the Midwest, recording USD 0.20 billion in 2026, following historical valuations of USD 0.15 billion in 2023, USD 0.16 billion in 2024, and USD 0.18 billion in 2025, on track to achieve USD 0.35 billion by 2032. The market is overwhelmingly anchored by the Chicago metropolitan area (Chicagoland), which represents the third-largest urban consumer market in the United States. Chicagoland supports an extensive infrastructure of corporate-owned and independent specialty referral hospitals, emergency networks, and feline-specific practices. Illinois veterinary practices exhibit high procurement volumes of direct digital radiography suites, multi-parameter vital signs monitors, high-frequency electrosurgical units, and digital dental radiography systems. The University of Illinois College of Veterinary Medicine in Urbana-Champaign serves as an academic catalyst, driving high-tier investments in cross-sectional imaging and surgical endoscopy.
Ohio generated USD 0.17 billion in 2026, rising from USD 0.13 billion in 2023, USD 0.14 billion in 2024, and USD 0.15 billion in 2025, projected to surpass USD 0.29 billion by 2032. Ohio features a well-balanced veterinary landscape spanning large metropolitan centers (Columbus, Cleveland, Cincinnati) and dense suburban and rural communities. The state exhibits an exceptionally strong orthopedic surgical caseload, stimulating steady procurement of locking compression plates, micro-power surgical drills, and orthopedic fixation consumables. The Ohio State University College of Veterinary Medicine in Columbus operates one of the busiest and most technologically advanced veterinary teaching hospitals in the nation, maintaining continuous capital equipment refresh cycles across its comprehensive oncology, neurology, soft-tissue, and equine surgical suites.
Michigan recorded USD 0.14 billion in 2026, moving from USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025, with expectations to reach USD 0.25 billion by 2032. The Detroit metropolitan area, along with Grand Rapids and Ann Arbor, forms the primary commercial spine of the state’s veterinary market. Michigan clinics maintain rigorous standards for anesthesia safety and critical care, driving strong capital turnover in precision anesthesia vaporizers, active waste gas scavenging systems, and smart infusion pumps. Michigan State University College of Veterinary Medicine in East Lansing contributes substantially to regional expertise, maintaining advanced diagnostic imaging, interventional cardiology, and orthopedic reconstruction platforms.
Indiana accounted for USD 0.10 billion in 2026, advancing from USD 0.08 billion in 2023, USD 0.08 billion in 2024, and USD 0.09 billion in 2025, forecast to attain USD 0.18 billion by 2032. Anchored by the Indianapolis metropolitan region, Indiana’s companion animal sector displays steady capital expenditure in direct digital radiography, point-of-care ultrasound, and veterinary dental equipment. Purdue University College of Veterinary Medicine in West Lafayette serves as a prominent clinical and research hub, having completed major hospital expansions that integrated advanced radiation therapy, helical CT, and specialized equine surgical suites.
Wisconsin generated USD 0.09 billion in 2026, rising from USD 0.07 billion in 2023, USD 0.07 billion in 2024, and USD 0.08 billion in 2025, projected to reach USD 0.16 billion by 2032. The state’s market is centered around Milwaukee and Madison, supported by the University of Wisconsin-Madison School of Veterinary Medicine. The institution’s renowned oncology and imaging departments drive high standards of care across private practices throughout the state, stimulating consistent demand for advanced ultrasound transducers, minimally invasive biopsy tools, and multi-parameter surgical monitors. The remaining Midwestern states, encompassing Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota, collectively contributed USD 0.15 billion in 2026 and are projected to reach USD 0.24 billion by 2032. This vast agricultural and suburban territory houses top-tier veterinary institutions (such as the University of Minnesota, University of Missouri, and Iowa State University) alongside thousands of mixed and small-animal practices that maintain continuous demand for durable, portable diagnostic X-ray units, general surgical instruments, and core clinical consumables.
Northeast
The Northeast recorded USD 0.57 billion in 2023, expanding to USD 0.63 billion in 2024, USD 0.69 billion in 2025, and USD 0.77 billion in 2026. The region is forecast to attain USD 1.29 billion by 2032, advancing at a CAGR of 9.00% during the forecast period. Capturing approximately 18.0% of total U.S. companion animal medical device revenue in 2026, the Northeast represents the most mature, densely populated, and clinically specialized regional market in the nation. While geographic expansion and new practice construction occur at a more measured pace than in the Sunbelt, the Northeast exhibits the highest concentration of board-certified veterinary specialists per square mile, unmatched pet owner disposable income, and exceptionally high clinical procedure billing rates.
New York stands as the dominant market in the Northeast, generating USD 0.27 billion in 2026, advancing from USD 0.20 billion in 2023, USD 0.22 billion in 2024, and USD 0.24 billion in 2025, on pace to reach USD 0.45 billion by 2032. New York City, Long Island, and Westchester County form an extraordinarily wealthy, pet-dense corridor where pet owners routinely demand the highest caliber of medical intervention. Specialized institutions such as the Schwarzman Animal Medical Center in Manhattan represent the pinnacle of veterinary device instrumentation, operating comprehensive multi-suite surgical facilities equipped with high-field MRI, helical CT, interventional radiology fluoroscopy, and intensive care hemodialysis. Upstate New York maintains an extensive network of multi-doctor community practices and emergency referral centers, reinforced by Cornell University College of Veterinary Medicine in Ithaca, an internationally preeminent center for veterinary orthopedic biomechanics, cardiology, and advanced imaging research.
Pennsylvania generated USD 0.18 billion in 2026, rising from USD 0.13 billion in 2023, USD 0.15 billion in 2024, and USD 0.16 billion in 2025, with long-term forecasts targeting USD 0.31 billion by 2032. The state’s market is concentrated within the Greater Philadelphia metropolitan area and the Pittsburgh urban corridor. Pennsylvania practices exhibit high clinical volumes in complex soft-tissue surgery, surgical oncology, and orthopedic stabilization, driving consistent capital procurement of advanced vessel-sealing devices, TPLO locking systems, and color Doppler ultrasound units. The University of Pennsylvania School of Veterinary Medicine (Penn Vet) operates both the Matthew J. Ryan Veterinary Hospital for small animals in Philadelphia and the New Bolton Center for large animals in Kennett Square, maintaining massive capital device inventories spanning standing equine robotic CT scanners to neonatal companion animal critical care incubators.
Massachusetts recorded USD 0.13 billion in 2026, advancing from USD 0.10 billion in 2023, USD 0.11 billion in 2024, and USD 0.12 billion in 2025, projected to attain USD 0.22 billion by 2032. The state’s market is centered in the Greater Boston metropolitan area, which boasts exceptional median household wealth, high pet health insurance penetration, and a dense concentration of life-science and medical technology professionals who prioritize sophisticated healthcare for their pets. Premier referral institutions, such as Angell Animal Medical Center in Boston, operate at the cutting edge of clinical medicine, driving rapid procurement of veterinary laparoscopy towers, advanced multi-parameter monitors, and smart infusion pumps. The Cummings School of Veterinary Medicine at Tufts University in Grafton further enriches regional clinical capabilities through ongoing advancements in veterinary cardiology, mechanical ventilation, and minimally invasive surgery.
New Jersey accounted for USD 0.11 billion in 2026, moving from USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025, forecast to achieve USD 0.18 billion by 2032. Characterized by high population density, affluent suburban communities feeding into both the New York City and Philadelphia economic hubs, and high consumer spending on veterinary wellness, New Jersey practices invest heavily in direct digital radiography, veterinary dental stations, and multi-gas anesthesia delivery systems. The remaining Northeastern states, comprising Connecticut, Maryland, Maine, New Hampshire, Rhode Island, and Vermont, collectively generated USD 0.08 billion in 2026 and are on track to achieve USD 0.13 billion by 2032. These New England states combine affluent suburban enclaves with rural companion animal and equine populations, maintaining steady capital device replacement cycles for compact diagnostic ultrasound, routine surgical power tools, and basic surgical consumables.
Key Market Players
The U.S. Companion Animal Medical Devices competitive landscape is characterized by a strategic mix of multi-billion-dollar global animal health conglomerates, specialized human-to-veterinary medical device crossover manufacturers, and focused veterinary medtech innovators.
The prominent key players operating in the U.S. companion animal medical devices industry include:
- IDEXX Laboratories, Inc.
- Zoetis Inc.
- Heska Corporation (Antech Diagnostics / Mars Petcare)
- Mindray Animal Medical (Mindray Medical International)
- Midmark Corporation
- Hallmarq Veterinary Imaging
- Covetrus, Inc.
- B. Braun Vet Care (B. Braun Melsungen AG)
- Jorgensen Laboratories, Inc. (JorVet)
- Sound Technologies (Sound Veterinary / VCA / Mars Petcare)
- scil animal care company GmbH (Covetrus)
- Vetland Medical
- Movora (Vimian Group – Kyon, BioMedtrix, Securos Surgical)
- Dextronix, Inc.
- Mila International, Inc.
IDEXX Laboratories, Inc. maintains an unmatched leadership position across the U.S. companion animal diagnostic ecosystem. While historically renowned for in-clinic benchtop chemistry and hematology analyzers, IDEXX has constructed a formidable diagnostic imaging and digital workflow enterprise. The company’s ImageVue and CR/DR direct digital radiography suites, combined with its proprietary IDEXX Web PACS cloud infrastructure, form the primary imaging backbone for thousands of community and specialty veterinary practices. IDEXX leverages its massive installed base of veterinary practice management software systems (including Cornerstone and Neo) to create friction-free, cloud-connected workflows where radiographic and diagnostic images automatically populate patient medical records and flow seamlessly into AI-assisted diagnostic pipelines, solidifying exceptional customer retention and continuous software licensing revenue.
Zoetis Inc. has aggressively expanded its device and diagnostic footprint to complement its dominant biopharmaceutical and vaccine portfolios. Through the strategic acquisition of Abaxis and subsequent internal medtech engineering investments, Zoetis provides the VetScan line of diagnostic platforms, point-of-care rapid analyzers, and related clinical monitoring devices. Zoetis capitalizes on its expansive field sales force and corporate enterprise contracting capabilities to bundle medical equipment, biological therapeutics, and parasiticides into unified corporate pricing agreements, establishing significant competitive barriers for standalone device manufacturers.
Heska Corporation, operating within Antech Diagnostics under the Mars Petcare umbrella, represents a major force in veterinary diagnostic imaging, point-of-care laboratory hardware, and clinical connectivity. Heska’s portfolio features the Element line of diagnostic platforms, high-definition digital radiography detectors, advanced ultrasound systems, and specialized veterinary infusion pumps. Following its integration into Mars Petcare, Heska enjoys direct, preferred access to the vast corporate clinic networks of Banfield, VCA, and BluePearl, creating an enormous internal corporate pipeline for capital device placement, software integration, and recurring consumable supply agreements.
Mindray Animal Medical has emerged as one of the most disruptive and rapidly expanding capital equipment providers in the United States. Leveraging the manufacturing scale and technological engineering of its parent human medtech organization, Mindray delivers high-tier medical hardware specifically calibrated for quadruped physiology at highly competitive price points. Mindray’s veterinary product lines encompass high-end cart-based and portable color Doppler ultrasound systems (such as the Vetus series), dedicated multi-parameter patient monitors (eMView and uMEC series) featuring veterinary-specific arrhythmia analysis, precision anesthesia delivery systems with integrated lung-protective ventilation, and advanced rigid endoscopy towers. Mindray’s rapid U.S. market share gains are driven by superior hardware reliability, intuitive touch-screen interfaces, and multi-year standard warranty structures that appeal to both corporate consolidators and independent practice owners.
Midmark Corporation serves as a cornerstone manufacturer of essential clinical infrastructure, anesthesia delivery systems, dental workstations, and monitoring hardware across the North American veterinary landscape. Midmark’s product portfolio includes the Matrx line of veterinary anesthesia machines, the VetPro digital dental radiography and mobile dental delivery carts, the Multiparameter Monitor lines, and comprehensive veterinary clinical casework, exam tables, and surgical lighting suites. Midmark distinguishes itself through extensive clinical education initiatives, practice design consulting services, and deep distribution relationships with major veterinary distributors such as Patterson Veterinary, Henry Schein Animal Health, and Covetrus.
Hallmarq Veterinary Imaging specializes in advanced, specialized cross-sectional diagnostic imaging platforms engineered exclusively for veterinary applications. Hallmarq is globally celebrated for developing the world’s first and leading standing equine 0.25-Tesla MRI system, which eliminates the mortality risks of general anesthesia in horses by enabling diagnostic imaging of the distal limb in standing, sedated patients. In the companion animal domain, Hallmarq markets a dedicated 1.5-Tesla high-field small animal MRI system featuring a unique veterinary-specific radiofrequency coil array, an integrated patient warming cradle, and a compact footprint that does not require liquid helium refilling or external RF shielding cages, drastically lowering the architectural and financial barriers to MRI installation in private specialty practices.
Covetrus, Inc. functions as a massive, multifaceted animal health technology and distribution power, operating across supply chain logistics, proprietary veterinary software, and specialized clinical device manufacturing. Through its medical device divisions and distribution channels, Covetrus supplies thousands of U.S. veterinary clinics with surgical instruments, anesthesia workstations, diagnostic monitors, IV fluid infusion devices, and recurring consumables. Covetrus leverages its proprietary practice management software platforms (including Pulse, AVImark, and ImproMed) to embed automated device supply reordering directly into clinic inventory workflows, creating a deeply entrenched, recurring consumable distribution model.
B. Braun Vet Care, a dedicated division of the global medtech leader B. Braun Melsungen AG, brings human-grade medical device engineering to companion animal surgery and critical care. B. Braun’s veterinary portfolio encompasses the Aesculap line of high-precision surgical hand instrumentation, advanced motor-driven orthopedic power tools, electrosurgical units, the Infusomat and Perfusor space-saving smart infusion and syringe pump systems, and advanced wound closure sutures. B. Braun dominates the high-acuity veterinary surgical and intensive care market, where board-certified veterinary surgeons demand the highest levels of metal craftsmanship, instrument balance, and infusion dosing precision.
Jorgensen Laboratories, Inc. (JorVet) represents one of the most established and trusted family-owned veterinary medical device and specialty instrumentation companies in the United States. JorVet maintains an exhaustive catalog spanning thousands of specialized veterinary products, including orthopedic surgical instruments, suture needles, anesthesia accessories, fluid administration sets, diagnostic refractometers, veterinary centrifuges, and physical examination tools. JorVet’s enduring competitive strength lies in its comprehensive catalog of niche, hard-to-source veterinary instruments, exceptional brand loyalty among independent practitioners, and longstanding distribution partnerships with every major national veterinary distributor.
Sound Technologies, a division of VCA and operating within the Mars Petcare family, is a premier provider of advanced digital radiography, veterinary ultrasound, and advanced imaging software. Sound’s TruDR digital radiography systems and NEXT ultrasound platforms are widely deployed across thousands of general and specialty practices nationwide. Sound’s strategic value is further amplified by its integrated tele-radiology networks and cloud-based image management platforms, which allow general practitioners to obtain rapid specialist consultations from board-certified veterinary radiologists within hours of image capture.
scil animal care company GmbH, operating as an integral part of Covetrus, is a major international provider of veterinary diagnostic imaging systems, orthopedic surgical solutions, and point-of-care laboratory hardware. scil’s imaging portfolio features the scil digital radiography flat-panel detectors, dedicated small animal ultrasound systems, and mobile computed tomography platforms. In the orthopedic sector, scil distributes precision TPLO locking plates and fracture fixation systems, supported by rigorous hands-on surgical training courses that educate general practitioners and surgical residents across North America.
Vetland Medical is an elite, American-based designer and manufacturer of critical care veterinary equipment, recognized specifically for engineering the safest, most reliable veterinary anesthesia systems in the industry. Vetland’s flagship products include the Landmark veterinary anesthesia machines, which incorporate patented safety features such as pressure-sensing safety pop-off valves that eliminate accidental patient lung barotrauma caused by closed scavenging lines. Vetland also manufactures high-reliability veterinary multi-parameter monitors, critical care oxygen concentrators, and specialized veterinary intensive care environmental chambers, maintaining an exceptional reputation among veterinary universities and specialty surgical centers.
Movora, established as the veterinary orthopedic and surgical umbrella entity within the global Vimian Group, represents the undisputed global powerhouse in veterinary orthopedics, neurosurgery, and advanced surgical implants. Movora unifies three legendary veterinary surgical innovators: BioMedtrix (pioneers of the universal canine total hip replacement system and total knee replacements), KYON (inventors of the advanced TPLO, TTA, and Zurich Cementless total hip systems), and Securos Surgical (leaders in orthopedic trauma fixation, surgical sutures, and surgical hand instruments). Movora commands an unassailable leadership position in canine joint reconstruction, spinal stabilization, and complex fracture repair, supported by extensive biomechanical clinical trial registries, proprietary patent portfolios, and global surgical certification masterclasses.
Dextronix, Inc. is an agile, highly specialized medical technology company focused on developing interventional cardiology, wireless telemetry, and implantable cardiovascular devices specifically for companion animals. Dextronix pioneered the commercial introduction of implantable veterinary cardiac pacemakers, transcatheter cardiac occlusion devices, and the HD+ wireless multi-lead veterinary telemetry monitoring system. By providing specialized interventional devices adapted for veterinary cardiovascular anatomy, Dextronix equips veterinary cardiologists with the clinical tools required to manage complex arrhythmias, heart block, and congenital vascular anomalies in canine and feline patients.
Mila International, Inc. is a globally respected, innovative designer and manufacturer of specialized veterinary medical consumables, catheters, and fluid management devices. Mila International focuses exclusively on identifying unmet clinical needs in veterinary patient access and critical care, engineering products specifically tailored to quadruped anatomy. The company’s portfolio includes specialized over-the-wire central venous catheter kits, peripherally inserted central catheters (PICC lines), thoracic chest drainage catheters, feline urinary catheters, nasogastric feeding tubes, and high-pressure infusion extension sets. Mila’s products are regarded as the gold standard within veterinary intensive care units, emergency hospitals, and university teaching centers throughout North America.
Recent Developments
The U.S. companion animal medical devices market has experienced significant strategic consolidation, rapid technological introductions, and structural industry realignments between 2024 and 2026.
Consolidation of diagnostic and veterinary technology assets reached a major milestone with the formal completion and post-acquisition operational integration of Heska Corporation into Mars Petcare’s Antech Diagnostics division. This transaction, completed in late 2023 for an enterprise valuation of approximately USD 1.3 billion, created an integrated diagnostic powerhouse spanning reference laboratory services, in-clinic point-of-care analyzers, and advanced digital imaging hardware. Throughout 2024 and 2025, Mars Petcare leveraged this consolidated entity to initiate fleet-wide equipment refresh programs across its massive network of more than 2,500 corporate veterinary hospitals, including VCA, Banfield, and BluePearl, deploying standardized digital radiography systems, cloud-connected ultrasound units, and proprietary software interfaces that link diagnostic hardware directly into centralized corporate health records.
Strategic acquisitions have similarly reshaped the orthopedic and minimally invasive surgical landscape. Movora, the veterinary surgical arm of Vimian Group, completed the targeted acquisition of specialized surgical instrument manufacturers and biomaterial developers across 2024 and 2025, expanding its clinical portfolio into advanced biological bone grafts, recombinant growth factors, and specialized micro-laparoscopic instruments. These transactions have enabled Movora to deliver complete procedural solutions—coupling specialized 3D surgical planning software with custom-manufactured patient-specific titanium implants and proprietary surgical power tools—reinforcing its dominant share across premier academic and private veterinary surgical institutions.
The integration of artificial intelligence into primary diagnostic imaging hardware has accelerated dramatically between 2024 and 2026. Leading digital radiography manufacturers, including IDEXX Laboratories, Sound Technologies, and Mindray Animal Medical, have commercialized next-generation direct digital radiography acquisition software embedded with deep-learning diagnostic algorithms. Clearances and commercial deployments throughout 2025 and 2026 have introduced real-time artificial intelligence algorithms capable of detecting and quantifying cardiomegaly via the Vertebral Heart Score, identifying pulmonary metastatic nodules down to 4mm, and detecting subtle subluxations and bone lysis within thirty seconds of plate exposure. These software innovations alleviate diagnostic turnaround bottlenecks caused by the ongoing shortage of board-certified veterinary radiologists, empowering emergency clinicians and general practitioners to initiate targeted medical and surgical interventions without delay.
Point-of-care diagnostic ultrasound has witnessed profound hardware miniaturization and performance upgrades. In late 2024 and 2025, several next-generation handheld ultrasound platforms equipped with ultra-wideband silicon transducers and wireless tablet connectivity entered the U.S. veterinary market. These ultra-portable devices offer specialized veterinary software algorithms that guide general practitioners through standard abdominal and thoracic ultrasound views, automatically calculating chamber volumes, bladder dimensions, and fluid pockets. This technology has expanded diagnostic ultrasound utilization out of specialized imaging suites and placed it directly into routine examination rooms, triage areas, and mobile veterinary service vans.
The regulatory environment governing veterinary medical devices has simultaneously experienced heightened scrutiny surrounding clinical electrical safety, laser radiation emission standards, and manufacturing quality consistency. While non-radiation-emitting veterinary devices continue to operate under streamlined FDA Center for Veterinary Medicine post-market surveillance without requiring human-style 510(k) premarket clearance, the FDA Center for Devices and Radiological Health has updated radiation safety compliance mandates for veterinary diagnostic X-ray, fluoroscopy, and CT systems. Manufacturers are increasingly required to demonstrate robust mechanical and electrical safety certifications, electromagnetic compatibility compliance, and software cybersecurity validation for connected veterinary medical platforms. Concurrently, veterinary medical device companies are proactively adopting ISO 13485 medical device quality management standards to satisfy the operational expectations of large corporate consolidators and to support potential future regulatory transitions.
Capital procurement behavior within U.S. veterinary hospital networks has normalized following the rapid post-pandemic surge in veterinary clinical caseloads. Between 2024 and 2026, practice owners and corporate procurement committees transitioned away from emergency, capacity-driven hardware purchases toward strategic fleet optimization, workflow automation, and long-term cost of ownership management. Procurement evaluations now prioritize medical devices that demonstrate high mean time between failures, comprehensive multi-year service level agreements, seamless two-way integration with cloud practice management software, and minimal operational complexity for credentialed veterinary technicians. Platforms that incorporate intuitive touchscreen interfaces, automated calibration cycles, and integrated staff safety mechanisms command premium pricing and capture significant market share across both corporate and independent clinical settings.
Conclusion
The U.S. Companion Animal Medical Devices Market is positioned to expand from USD 4.26 billion in 2026 to approximately USD 7.48 billion by 2032, advancing at a CAGR of 9.84% during the forecast period. Historical market performance from approximately USD 3.15 billion in 2023 to USD 3.85 billion in 2025 reflects the consistent resilience and underlying financial strength of the companion animal healthcare sector, driven by sustained post-pandemic pet ownership, the cultural normalization of pet humanization, rapid corporate veterinary practice consolidation, and the expanding penetration of comprehensive pet health insurance policies.
The fundamental long-term growth thesis extends far beyond a simple baseline increase in the domestic companion animal census. The veterinary healthcare industry is undergoing a structural transformation in the standard of clinical care, shifting from basic symptomatic treatment toward human-grade specialty interventions, proactive geriatric disease management, and minimally invasive interventional procedures. Veterinary hospitals and multi-specialty referral centers will continue to anchor capital equipment expenditure for advanced cross-sectional imaging, surgical operating suites, and critical care monitoring platforms. Simultaneously, independent community clinics and mobile veterinary practices will drive high-volume, rapid growth in point-of-care diagnostic ultrasound, digital dental radiography, wireless telemetry monitors, and recurring clinical consumables.
The most lucrative commercial opportunities through 2032 will center on software-integrated and connected medical devices, specialized veterinary orthopedics, minimally invasive laparoscopy, advanced patient monitoring ecosystems, and high-frequency surgical consumables. Point-of-care handheld ultrasound devices, direct digital radiography systems embedded with real-time artificial intelligence diagnostic screening, advanced bipolar vessel-sealing platforms, anatomically contoured titanium TPLO and fracture fixation locking plates, total joint replacement systems, smart veterinary infusion pumps with comprehensive drug error reduction libraries, and feline-specific interventional micro-catheters represent high-growth product categories capable of outperforming broader market averages.
Canine patients will maintain their status as the dominant revenue-generating animal type, supported by substantial population numbers, elevated predisposition to severe orthopedic and oncologic pathologies, and high pet insurance reimbursement density. Concurrently, the feline segment will exhibit the fastest relative growth trajectory as veterinary clinics establish cat-friendly hospital environments and deploy miniaturized diagnostic and therapeutic instrumentation specifically tailored for feline anatomy and chronic renal, cardiovascular, and metabolic disorders. Orthopedics and traumatology will remain the highest-value clinical application, while neurology, cardiology, and minimally invasive soft-tissue surgery capture an expanding share of specialty procedural revenue.
Geographically, the South will maintain its preeminent position as the largest regional market by absolute revenue, driven by expansive suburban populations, high pet ownership demographics, lower facility construction overhead, and dense networks of corporate-backed referral hospitals across Texas, Florida, North Carolina, and Georgia. The West will lead the nation in technology-driven growth and premium clinical adoption, anchored by California’s massive veterinary healthcare economy, high household incomes, and early commercial uptake of connected digital health platforms, artificial intelligence imaging solutions, and advanced surgical techniques. The Northeast will continue to exert profound clinical influence through its unmatched density of premier academic veterinary institutions, board-certified specialists, and high per-procedure billing rates. The Midwest will provide a highly stable, commercially significant foundation supported by large suburban pet populations, world-class veterinary colleges, and expansive sporting and companion equine sectors.
For medical device manufacturers, private equity investors, healthcare supply chain distributors, and veterinary corporate executives, competitive victory in the U.S. companion animal medical devices space through 2032 will not be achieved through isolated hardware specifications alone. Long-term leadership will be captured by companies that successfully control integrated clinical care pathways. Manufacturers that deliver comprehensive ecosystems—seamlessly unifying diagnostic acquisition hardware, artificial intelligence decision support, cloud-connected image archiving, precision surgical instrumentation, biomechanically validated implants, specialized training masterclasses, and dependable field service infrastructure—will establish an unassailable strategic advantage. As human and animal healthcare standards continue to converge, medtech enterprises that empower veterinary clinicians to deliver superior clinical outcomes with elevated workflow efficiency and minimized operational friction will capture the defining share of market value across the United States.